Comparison between coagulation factor VIII quantified with one-stage activity assay and with mass spectrometry in haemophilia A patients: Proof of principle.

ABSTRACT:

Introduction

Haemophilia A is a hereditary bleeding disorder caused by a factor VIII (FVIII) deficiency. As biomarker, FVIII activity is used to classify disease severity and to monitor treatment. The one-stage clotting assay (OSA) is performed to measure FVIII activity, but OSA's limitations may result in misclassification of disease severity or suboptimal monitoring of treatment. Measurement of FVIII plasma concentration with liquid chromatography-tandem mass spectrometry (LC-MS/MS) might overcome these challenges. The objective is to investigate the correlation between FVIII activity and concentration, and determinants for differences between the two methods.

Methods

In this cross-sectional study, all haemophilia A patients receiving standard-of-care were eligible for inc

SUBMITTER: Donners AAMT 

PROVIDER: S-EPMC7754357 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature